Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26618744 | 0.83 | GRIN2D (0.45) | ALDH1A1TDP1CYP1A2GRIN2DGRIN3B | |
| SCHEMBL18322060 | 0.82 | MAPT (0.40) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL31129475 | 0.79 | SMN1; SMN2 (0.34) | ALDH1A1TDP1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL203696 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TDP1CYP1A2GRIN2DGRIN3B | |
| SCHEMBL21412120 | 0.73 | LMNA (0.39) | ALDH1A1TDP1CYP1A2SMN1; SMN2MAPT | |
| SCHEMBL29207333 | 0.73 | MAPT (0.40) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A | |
| SCHEMBL27162785 | 0.71 | MAPT (0.39) | ALDH1A1TDP1CYP1A2GRIN2DGRIN3B | |
| SCHEMBL31257424 | 0.71 | CYP1A2 (0.41) | ALDH1A1TDP1CYP1A2GRIN2DGRIN3B | |
| SCHEMBL19776329 | 0.71 | PGK1 (0.40) | ALDH1A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL26922015 | 0.71 | GAA (0.41) | ALDH1A1SMN1; SMN2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3766878-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-03-16 | — | — | EP | disclosed |
| EP-3766878-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2021-01-20 | — | — | EP | disclosed |
| EP-3307729-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-09-02 | — | — | EP | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-20190224212-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2019-07-25 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10272095-B2 | NRF2 regulators | GlaxoSmithKline Intellectual Propert Development Limited (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180169110-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-21 | — | — | US | disclosed |
| WO-2018104766-A1 | 3-(2,3-DIHYDRO-1H-INDEN-5-YL)PROPANOIC ACID DERIVATIVES AND THEIR USE AS NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-14 | — | — | WO | disclosed |
| EP-3307729-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016203401-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10272095-B2 | NRF2 regulators | NFE2L2, KEAP1, NQO1 | ALDH1A1 621/4885TDP1 4360/4885CYP1A2 465/4885 |
| US-20190224212-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ALDH1A1 621/4885TDP1 4360/4885CYP1A2 465/4885 |
| US-20180169110-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | ALDH1A1 621/4885TDP1 4360/4885CYP1A2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.